Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 2180.

https://doi.org/10.1182/blood-2024-200423

Published: 2024

Journal Articles

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Blood (2023) 142 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2023-182831

Published: 2023

Journal Articles

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 7089.

https://doi.org/10.1182/blood-2023-187095

Published: 2023

Journal Articles

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2023-185685

Published: 2023

Journal Articles

Comparative Study for Haplo, MSD and MUD Allo-Hcts for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 660.

https://doi.org/10.1182/blood-2023-185557

Published: 2023

Journal Articles

Comparative Study for Haplo, MSD and MUD Allo-Hcts for Core-Binding Factor AML Patients in CR2: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 659.

https://doi.org/10.1182/blood-2023-186735

Published: 2023

Journal Articles

Autologous Versus Haploidentical Stem Cell Transplantation in Adult Patients with Intermediate Risk Actue Myelogenous Leukemia in First Complete Remission and Undetectable Minimal Residual Disease: A Global Preliminary Analysis of Chinese Data

Jia Chen, Yiyang Ding, Xi Zhang, Erlie Jiang, Lin Liu, He Huang, Jiong Hu, Jishi Wang, Yanming Zhang, Myriam Labopin, Irma Khvedelidze, Emmanuelle Polge, Arnon Nagler, Mohamad Mohty, Depei Wu, Norbert Claude Gorin, Sr.

Blood (2022) 140 (Supplement 1): 12952–12953.

https://doi.org/10.1182/blood-2022-165709

Published: 2022

Journal Articles

Comparable Outcomes Following Non-First-Degree and First-Degree Related Donor Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia Patients in Complete Remission: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Yishan Ye, Myriam Labopin, Jia Chen, Zafer Gulbas, Xi Zhang, Yener Koc, Didier Blaise, Fabio Ciceri, Emmanuelle Polge, Houhou Mohamad, Lin Li, Yi Luo, Depei Wu, He Huang, Mohamad Mohty, Norbert Claude Gorin, Sr.

Blood (2022) 140 (Supplement 1): 10603–10605.

https://doi.org/10.1182/blood-2022-158482

Published: 2022

Journal Articles

Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Arnon Nagler, Jacques-Emmanuel Galimard, Myriam Labopin, Didier Blaise, William Arcese, Depei Wu, Gwendolyn Van Gorkom, Marie Thérèse Rubio, Tobias Gedde-Dahl, Anne Huynh, Francesco Lanza, Norbert Claude Gorin, Sr., Mohamad Mohty, Silvia Maria Trisolini, Arnaud Pigneux

Blood (2021) 138 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2021-145031

Published: 2021

Journal Articles

NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry

Mohamed Amine Bekadja, Ariane Boumendil, Sr., PhD, Didier Blaise, MD, Patrice Chevalier, MD PhD, Karl S Peggs, MD PhD, Gilles Salles, MD PhD, Sebastian Giebel, Sr., Jürgen Finke, Sr., MD PhD, William Arcese, MD PhD, Noel Milpied, Hervé Finel, Sr., MD PhD, Norbert Claude Gorin, Sr., MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-133900

Published: 2020

Journal Articles

Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Sebastian Giebel, Sr., Myriam Labopin, MD, Mohamed Houhou, Denis Caillot, Jürgen Finke, Sr., MD PhD, Didier Blaise, MD, Nathalie Fegueux, Mark Edward Ethell, MD, Jan J. Cornelissen, MD PhD, Edouard Forcade, MD PhD, Ibrahim Yakoub-Agha, Federico Lussana, MD, Johan Maertens, Jean-Henri Bourhis, Pavel Jindra, MD PhD, Norbert Claude Gorin, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140328

Published: 2020

Journal Articles

FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT

Roni Shouval, MD PhD, Myriam Labopin, MD, David Bomze, MSc, Gabriela M Baerlocher, Robin Foà, MD, Didier Blaise, Mathias Haenel, MD, Edouard Forcade, MD, Anne Huynh, MD, Riccardo Saccardi, MD, Giuseppe Milone, MDPhD, Tsila Zuckerman, MD, Péter Reményi, MD, Jordi Esteve, MD PhD, Norbert Claude Gorin, MDPhD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 609.

https://doi.org/10.1182/blood-2018-99-111614

Published: 2018

Journal Articles

Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study

Blood (2017) 130 (Supplement 1): 907.

https://doi.org/10.1182/blood.V130.Suppl_1.907.907

Published: 2017

Journal Articles

Transplant Outcome for Secondary Acute Myeloid Leukemia Based on Prior Hematological Disease or Solid Malignancy — on Behalf of the ALWP of the EBMT

Blood (2017) 130 (Supplement 1): 3320.

https://doi.org/10.1182/blood.V130.Suppl_1.3320.3320

Published: 2017

Journal Articles

Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia : Better Outcomes with Busulfan and Melphalan Compared with Busulfan and Cyclophosphamide in High Risk Patients Autografted in First Complete Remission

Norbert Claude Gorin, MDPhD, Myriam Labopin, MD, Didier Blaise, Pierre-Yves Dumas, MD, Thomas Pabst, MD, Silvia Maria Trisolini, William Arcese, MD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 338.

https://doi.org/10.1182/blood.V130.Suppl_1.338.338

Published: 2017

Journal Articles

Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT

Blood (2015) 126 (23): 863.

https://doi.org/10.1182/blood.V126.23.863.863

Published: 2015

Journal Articles

Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT

Norbert Claude Gorin, Pr, MD PhD, Myriam Labopin, MD, Tomasz Czerw, MD, Kurt Leibundgut, MD, Didier Blaise, MD PhD, Pierre Yves Dumas, MD PhD, Damir Nemet, MD PhD, William Arcese, MD, Roberto Foa, MD, Wu Depei, MD, Anne Huynh, MD, Tsila Zuckerman, MD, Ellen Meijer, MDPhD, Seckin Cagirgan, PhD MD, Jan Cornelissen, MD PhD, Mohamad Mohty, MD PhD, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 926.

https://doi.org/10.1182/blood.V126.23.926.926

Published: 2015

Journal Articles

Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation

Blood (2015) 126 (23): 155.

https://doi.org/10.1182/blood.V126.23.155.155

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT

Blood (2015) 126 (23): 63.

https://doi.org/10.1182/blood.V126.23.63.63

Published: 2015

Journal Articles

Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Francesco Saraceni, MD, Myriam Labopin, MD, Norbert Claude Gorin, MD, Didier Blaise, MD PhD, Reza Tabrizi, Liisa Volin, MD PhD, Jan Cornelissen, MD PhD, Jean-Yves Cahn, Patrice Chevallier, MD PhD, Charles Craddock, BM, FRCP, FRCPath, Depei Wu, MD, Anne Huynh, MD, William Arcese, MD, Mohamad Mohty, MD, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 3216.

https://doi.org/10.1182/blood.V126.23.3216.3216

Published: 2015

NARROW

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Comparative Study for Haplo, MSD and MUD Allo-Hcts for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Comparative Study for Haplo, MSD and MUD Allo-Hcts for Core-Binding Factor AML Patients in CR2: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Autologous Versus Haploidentical Stem Cell Transplantation in Adult Patients with Intermediate Risk Actue Myelogenous Leukemia in First Complete Remission and Undetectable Minimal Residual Disease: A Global Preliminary Analysis of Chinese Data

NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry

Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT

Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study

Transplant Outcome for Secondary Acute Myeloid Leukemia Based on Prior Hematological Disease or Solid Malignancy — on Behalf of the ALWP of the EBMT

Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia : Better Outcomes with Busulfan and Melphalan Compared with Busulfan and Cyclophosphamide in High Risk Patients Autografted in First Complete Remission

Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT

Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT

Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT

Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only